医学
指南
重症监护医学
肝损伤
药品
临床试验
肝病
疾病
临床实习
病理
内科学
药理学
物理疗法
出处
期刊:PubMed
日期:2023-04-20
卷期号:31 (4): 355-384
被引量:16
标识
DOI:10.3760/cma.j.cn501113-20230419-00176-1
摘要
Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, anti-neoplastic drugs), and signal and assessment of DILI in clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI